PMID- 29519711
OWN - NLM
STAT- MEDLINE
DCOM- 20190401
LR  - 20190401
IS  - 1938-0674 (Electronic)
IS  - 1533-0028 (Linking)
VI  - 17
IP  - 2
DP  - 2018 Jun
TI  - Association of CDX2 Expression With Survival in Early Colorectal Cancer: A 
      Systematic Review and Meta-analysis.
PG  - 97-103
LID - S1533-0028(17)30507-8 [pii]
LID - 10.1016/j.clcc.2018.02.001 [doi]
AB  - CDX2 is a homeobox gene encoding transcriptional factors for intestinal 
      organogenesis and represents a specific marker of colorectal adenocarcinoma (CRC) 
      differentiation. We have evaluated if CDX2 expression is associated with better 
      overall and disease-free survival (OS and DFS) in patients with CRC. PubMed, 
      SCOPUS, EMBASE, The Cochrane Library, and Web of Science (from inception to July 
      2017) were systematically reviewed for relevant studies on adult patients with 
      CRC where OS and DFS were calculated according to CDX2 expression in uni- or 
      multivariate analysis were included. Hazard ratio (HR) for mortality and/or 
      disease progression was calculated. The search produced 16 studies suitable for 
      inclusion (6291 individual patients). The meta-analysis showed a reduced risk of 
      death for patients with CDX2-positive CRC in 14 studies (HR, 0.5; 95% confidence 
      interval [CI], 0.38-0.66; P < .001 according to random effect model). In 6 
      studies where only DFS data was available, CDX2 expression led to a 52% lower 
      risk of relapse or death (HR, 0.48; 95% CI, 0.39-0.59; P < .001 according to 
      random effect model). The results did not change as a function of ethnicity, type 
      of study, CDX2 detection modality, or stage. Interestingly, in stages II to III, 
      CDX2 expression was associated with a 70% lower risk of death (HR, 0.3; 95% CI, 
      0.12-0.77; P = .01). CDX2 expression confirms to be a strong prognostic factor in 
      stage II and III CRC. In this setting, along with other clinical and pathologic 
      factors, the lack of expression of CDX2 may be considered an important variable 
      when deciding for adjuvant chemotherapy.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Tomasello, Gianluca
AU  - Tomasello G
AD  - Oncology Unit, Oncology Department, ASST Ospedale di Cremona, Cremona, Italy.
FAU - Barni, Sandro
AU  - Barni S
AD  - Oncology Unit, Oncology Department, ASST Bergamo Ovest, Treviglio, Bergamo, 
      Italy.
FAU - Turati, Luca
AU  - Turati L
AD  - Surgery Unit, ASST Bergamo Ovest, Treviglio, Bergamo, Italy.
FAU - Ghidini, Michele
AU  - Ghidini M
AD  - Oncology Unit, Oncology Department, ASST Ospedale di Cremona, Cremona, Italy.
FAU - Pezzica, Ezio
AU  - Pezzica E
AD  - Pathology Unit, ASST Bergamo Ovest, Treviglio, Bergamo, Italy.
FAU - Passalacqua, Rodolfo
AU  - Passalacqua R
AD  - Oncology Unit, Oncology Department, ASST Ospedale di Cremona, Cremona, Italy.
FAU - Petrelli, Fausto
AU  - Petrelli F
AD  - Oncology Unit, Oncology Department, ASST Bergamo Ovest, Treviglio, Bergamo, 
      Italy. Electronic address: faupe@libero.it.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20180215
PL  - United States
TA  - Clin Colorectal Cancer
JT  - Clinical colorectal cancer
JID - 101120693
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CDX2 Transcription Factor)
RN  - 0 (CDX2 protein, human)
SB  - IM
MH  - Adenocarcinoma/metabolism/mortality/*pathology
MH  - Biomarkers, Tumor/*analysis
MH  - CDX2 Transcription Factor/*biosynthesis
MH  - Colorectal Neoplasms/metabolism/mortality/*pathology
MH  - Disease-Free Survival
MH  - Humans
OTO - NOTNLM
OT  - Adjuvant
OT  - Biomarker
OT  - Chemotherapy
OT  - Prognosis
OT  - Stage II-III
EDAT- 2018/03/10 06:00
MHDA- 2019/04/02 06:00
CRDT- 2018/03/10 06:00
PHST- 2017/12/08 00:00 [received]
PHST- 2018/01/29 00:00 [revised]
PHST- 2018/02/08 00:00 [accepted]
PHST- 2018/03/10 06:00 [pubmed]
PHST- 2019/04/02 06:00 [medline]
PHST- 2018/03/10 06:00 [entrez]
AID - S1533-0028(17)30507-8 [pii]
AID - 10.1016/j.clcc.2018.02.001 [doi]
PST - ppublish
SO  - Clin Colorectal Cancer. 2018 Jun;17(2):97-103. doi: 10.1016/j.clcc.2018.02.001. 
      Epub 2018 Feb 15.